• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT® (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT® technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

Our Value Proposition

KemPharm® believes that its LAT® technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT® (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

Learn more about LAT®

March 3, 2021

Featured Publication

KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD

Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET   Celebration, FL – March 2, 2021 – KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture
  • KemPharm Reports First Quarter 2021 Financial...

  • KemPharm Announces Serdexmethylphenidate (SDX...

  • KemPharm to Report First Quarter 2021 Results